Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
HIV Drug Juluca Gets Japan Approval: ViiV
ViiV Healthcare said on November 26 that its HIV combo treatment Juluca (dolutegravir + rilpivirine) - the first single-pill, two-drug regimen - is now approved in Japan for the maintenance treatment of HIV-1 infection. Juluca combines the company’s dolutegravir, the…
To read the full story
Related Article
- ViiV’s HIV Drug Juluca Now Available in Japan
December 21, 2018
- ViiV’s HIV Drug Juluca to Join NHI Price List on Dec. 12
December 5, 2018
BUSINESS
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
- FDA Puts Regenxbio’s MPS II Gene Therapy Back on Clinical Hold
August 25, 2026
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
- Daiichi Sankyo Taps Ken Keller as New Commercial Chief in Global Revamp
August 25, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…